Recon: HHS announces first 10 drugs for Medicare price negotiations; Pfizer expects to resume production at Tornado-hit facility in Q4

• Here are the 10 drugs that will be up first for Medicare price negotiation (STAT) (Reuters) (Endpoints)
• Winners and losers from Medicare’s list of drugs subject to price negotiation (STAT)
• Explainer: Why the US is negotiating the price of 10 drugs (Reuters)
• Factbox: Court challenges to Medicare drug price negotiation plan (Reuters)
• FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs (STAT)
• Bristol Myers Squibb's Reblozyl, chasing $4B sales target, wins key FDA label expansion (Fierce Pharma)
• Roche’s Seven-Minute Tecentriq Jab Wins First Ever Regulatory Approval (Pink Sheet)
• A 3-Month Delay For A Better Label: US FDA User Fee Goal Extensions Are Usually Good News (Pink Sheet)
• FDA grants Orphan Drug Designation to Faron’s bexmarilimab in AML (Pharma Times)

• NHS sales levy ‘will leave Britain further behind global rivals’ (The Times of London)
• Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers (Pink Sheet)
• Takeda and ImmunoGen partner to develop and commercialise Elahere in Japan (Pharma Times)
• Three new UK Approved Bodies to certify medical devices announced by the MHRA (MHRA)

• Pfizer could restart production at tornado-hit plant by early Q4 (Reuters)
• Exclusive: Catalent to explore options after Elliott deal-sources (Reuters)
• Amgen launches new 'Lower Your LDL Cholesterol Now' campaign backed by the American Heart Association (Fierce Pharma)
• Arcutis launches branded Zoryve ad for a 'Cream That Can' as it eyes streaming services for new campaign (Fierce Pharma)
• PacBio, once slated to be acquired by Illumina, is taking on the DNA giant (Endpoints)
• Celularity signs on to do contract research for Regeneron (Endpoints)
• Apellis trims staff, shrinks R&D plans to save money in face of looming competition in ophthalmology (Endpoints)
• Novartis nixes PhII TGFß antibody — and one-time 'wild card' — after benefit-risk assessment (Endpoints)
• Ginkgo teams up with Google Cloud; Two biotechs raise money through private placements (Endpoints)
• Lilly’s Cholesterol Pill Shows Early Promise in Phase I Study (BioSpace)

• As competition looms, Insulet sues a rival for allegedly stealing trade secrets on diabetes tech (STAT)
• ProMED issues ultimatum to striking moderators, as questions about site’s future persist (STAT)
• Bristol Myers Squibb partners with Cellares for robotic production of pipeline CAR-T drug (Fierce Pharma)
• OTS Software Guidance Update Underscores Industry Advancements (MedTech Insight)

• Pfizer, BioNTech challenge Moderna COVID-19 vaccine patents at US Patent Office (Reuters)
• Medicare Floats Essential Medicine ‘Buffer Stock’ Incentive For Hospitals (Pink Sheet)
• Nine Best Practices For Creating And Implementing A Risk Management Plan (MedTech Insight)
• Hopes dim for Medtronic hypertension treatment after FDA panel rebuff (MedTech Dive)
• Medtronic identifies patients at increased risk of heart pump failure (MedTech Dive)
• 3M reaches $6B settlement to resolve combat earplug lawsuits (MedTech Dive)
• GE HealthCare rolls out software to speed assessment of AFib patients (MedTech Dive)